Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 113, Issue 2, Pages 232-241
Publisher
Springer Nature
Online
2015-07-01
DOI
10.1038/bjc.2015.238
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor Treating Fields Perturb the Localization of Septins and Cause Aberrant Mitotic Exit
- (2015) Nidhi Gera et al. PLoS One
- New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape
- (2014) Deepak Mittal et al. CURRENT OPINION IN IMMUNOLOGY
- NT-40 * Interim Analysis of the EF-14 Trial: A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM
- (2014) R. Stupp et al. NEURO-ONCOLOGY
- Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma
- (2014) Eric T. Wong et al. Cancer Medicine
- Long-term outcomes of surgical resection with or without adjuvant radiation therapy for treatment of spinal ependymoma: a retrospective multicenter study by the Korea Spinal Oncology Research Group
- (2013) S.-H. Lee et al. NEURO-ONCOLOGY
- Immunosurveillance as a regulator of tissue homeostasis
- (2013) Laura Senovilla et al. TRENDS IN IMMUNOLOGY
- Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
- (2012) D A Reardon et al. BRITISH JOURNAL OF CANCER
- VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
- (2012) Kan V. Lu et al. CANCER CELL
- NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
- (2012) Roger Stupp et al. EUROPEAN JOURNAL OF CANCER
- NovoTTF-100A: a new treatment modality for recurrent glioblastoma
- (2012) Ekokobe Fonkem et al. Expert Review of Neurotherapeutics
- Dacarbazine-Mediated Upregulation of NKG2D Ligands on Tumor Cells Activates NK and CD8 T Cells and Restrains Melanoma Growth
- (2012) Alice Hervieu et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide
- (2011) Stuart A. Grossman et al. CLINICAL CANCER RESEARCH
- Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma
- (2011) B. Raychaudhuri et al. NEURO-ONCOLOGY
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Bevacizumab for Malignant Gliomas
- (2010) Fabio M. Iwamoto et al. ARCHIVES OF NEUROLOGY
- The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy
- (2010) A. K. Hsu et al. BLOOD
- Prognostic significance and mechanism of Treg infiltration in human brain tumors
- (2010) Joannes F.M. Jacobs et al. JOURNAL OF NEUROIMMUNOLOGY
- The anticancer immune response: indispensable for therapeutic success?
- (2008) Laurence Zitvogel et al. JOURNAL OF CLINICAL INVESTIGATION
- Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
- (2008) A. D. Norden et al. NEUROLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now